To ascertain whether there is a connection between the COVID-19 mRNA vaccinations and myocarditis, pharmaceutical companies have started researching the long-term effects of these vaccines.
When the Food and Medicine Administration approved the use of the firms’ drug in August 2021, Pfizer and BioNTech were required to carry out the study.
One research was to be finished by 2024, while a longer, five-year study was to be finished by 2026, according to the letter.
In a letter similar to this one sent to Moderna in January, it was requested that one research be finished by 2023 and the longer-term study by 2028.
Two trials for Moderna have started, according to NBC News. According to the outlet, Pfizer will soon begin its testing. Early results might be made public in the new year, according to NBC.
An inflammation of the heart muscle is known as myocarditis. Pericarditis, as defined by the Centers for Disease Control and Prevention, is an inflammation of the outer lining of the heart.
It has been widely contested whether there is any connection between the COVID immunizations and heart problems, but some data points in that direction.
CDC Admits Post-Vaccine Myocarditis Concerns That Were Labeled Covid Misinformation Are Legithttps://t.co/T3Yjm1tFy9
— The Federalist (@FDRLST) September 9, 2022
Within three weeks of receiving the second dosage of the vaccination, there is an increased risk of cardiac problems, according to a study published in the Journal of the American College of Cardiology by Canadian researchers.
According to a press release from the American College of Cardiology, “Some rare, but serious, side effects have been observed after both [the Moderna and Pfizer] vaccines, mainly myocarditis.”
35.6 cases per million were reported of myocarditis within 21 days of the second treatment, according to research. Around two cases of myocarditis per million people were reported in the general population in 2018.
There is a correlation, according to a research in the Annals of Internal Medicine, even though the risk is minimal.
“We found that myocarditis/pericarditis 0 to 7 days after mRNA vaccination in persons aged 5 to 39 years occurred in approximately 1 in 200 000 doses after the first dose and 1 in 30 000 doses after second dose of the primary series, and 1 in 50 000 doses after the first booster,” the report stated.
Young males had the highest risk of myocarditis after getting the vaccine, according to both trials.
More on this story via The Western Journal